These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26320376)

  • 21. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
    Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
    Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
    de Bono JS
    Eur Urol; 2017 Feb; 71(2):e56. PubMed ID: 27544577
    [No Abstract]   [Full Text] [Related]  

  • 23. How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue.
    Francini E; Roviello G
    Tumour Biol; 2014 Aug; 35(8):7391-2. PubMed ID: 24874054
    [No Abstract]   [Full Text] [Related]  

  • 24. Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013.
    Mehra N; Dolling D; de Bono J
    Eur Urol; 2018 Sep; 74(3):e69-e70. PubMed ID: 29866468
    [No Abstract]   [Full Text] [Related]  

  • 25. Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.
    Van Praet C; Rottey S; Van Hende F; Pelgrims G; Demey W; Van Aelst F; Wynendaele W; Gil T; Schatteman P; Filleul B; Schallier D; Machiels JP; Schrijvers D; Everaert E; D'Hondt L; Werbrouck P; Vermeij J; Mebis J; Clausse M; Rasschaert M; Van Erps J; Verheezen J; Van Haverbeke J; Goeminne JC; Lumen N
    Urol Oncol; 2016 Jun; 34(6):254.e7-254.e13. PubMed ID: 26850781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
    Conteduca V; Lolli C; De Giorgi U
    Eur Urol; 2016 Dec; 70(6):e168-e169. PubMed ID: 27255584
    [No Abstract]   [Full Text] [Related]  

  • 27. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
    von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
    Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
    Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E
    Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
    Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
    Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
    Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
    Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re: Michael T. Schweizer, Xian C. Zhou, Hao Wang, et al. The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2014;66:646-52.
    O'Cathail M; Sundar S
    Eur Urol; 2015 Jun; 67(6):e113-e114. PubMed ID: 25534667
    [No Abstract]   [Full Text] [Related]  

  • 33. [Mechanisms of Resistance in Antihormone Therapies of Advanced Prostate Cancer].
    Thelen P; Gschwend J; Wolff JM; Miller K
    Aktuelle Urol; 2016 Feb; 47(1):79-85. PubMed ID: 26814975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.
    Del Re M; Biasco E; Crucitta S; Derosa L; Rofi E; Orlandini C; Miccoli M; Galli L; Falcone A; Jenster GW; van Schaik RH; Danesi R
    Eur Urol; 2018 Jan; 73(1):e11-e12. PubMed ID: 28801127
    [No Abstract]   [Full Text] [Related]  

  • 35. Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al.'s Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e51-2.
    On Behalf Of Ema
    Eur Urol; 2019 Mar; 75(3):e53. PubMed ID: 30658854
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors.
    Procopio G; Grassi P; Testa I; Verzoni E; Torri V; Salvioni R; Valdagni R; de Braud F
    Am J Clin Oncol; 2015 Oct; 38(5):479-82. PubMed ID: 24064757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51.
    Hölscher T; Lohaus F; Wirth M; Troost EGC
    Eur Urol; 2019 Oct; 76(4):e103-e104. PubMed ID: 31256943
    [No Abstract]   [Full Text] [Related]  

  • 38. Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience.
    Ramudo-Cela L; Balea-Filgueiras J; Vizoso-Hermida JR; Martín-Herranz I
    J Oncol Pharm Pract; 2017 Dec; 23(8):615-619. PubMed ID: 27753628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
    Basset V; Flamand V; Crouzet S; Ploussard G
    Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
    van Soest RJ; de Wit R
    Eur Urol; 2017 Jan; 71(1):e9-e10. PubMed ID: 27746063
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.